You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Dow
Baxter
Colorcon
McKesson

Last Updated: August 13, 2020

DrugPatentWatch Database Preview

SELEGILINE HYDROCHLORIDE - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for selegiline hydrochloride and what is the scope of freedom to operate?

Selegiline hydrochloride is the generic ingredient in three branded drugs marketed by Somerset, Apotex, Dava Pharms Inc, Lannett Co Inc, Rising, Bausch, Apotex Inc, Boscogen, Chartwell Molecules, Cosette, G And W Labs Inc, MLV, and Mylan, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for selegiline hydrochloride. Four suppliers are listed for this compound.

Recent Clinical Trials for SELEGILINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of OxfordN/A
University of South FloridaPhase 4
Mood and Anxiety Research, IncPhase 3

See all SELEGILINE HYDROCHLORIDE clinical trials

US Patents and Regulatory Information for SELEGILINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex SELEGILINE HYDROCHLORIDE selegiline hydrochloride CAPSULE;ORAL 075321-001 Dec 4, 1998 AB RX No Yes   Start Trial   Start Trial   Start Trial
Apotex Inc SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074871-001 Jun 6, 1997 AB RX No Yes   Start Trial   Start Trial   Start Trial
Lannett Co Inc SELEGILINE HYDROCHLORIDE selegiline hydrochloride CAPSULE;ORAL 075145-001 Sep 15, 2003 DISCN No No   Start Trial   Start Trial   Start Trial
Boscogen SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074912-001 Apr 30, 1998 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SELEGILINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch ZELAPAR selegiline hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021479-001 Jun 14, 2006   Start Trial   Start Trial
Bausch ZELAPAR selegiline hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021479-001 Jun 14, 2006   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Mallinckrodt
Medtronic
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.